BioSpace News Archive

BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, released the following year-end message.

SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, announced that it has been selected for addition to the NASDAQ Biotechnology Index®, effective prior to market open on Monday, December 20, 2021.

Lineage Cell Therapeutics, Inc., announced that Lineage and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and license agreement with Roche and Genentech for the development and commercialization of a retinal pigment epithelium cell therapy for the treatment of ocular disorders, including advanced dry age-related macular degeneration with geographic atrophy.

Henry Schein Celebrates 23rd Annual ‘Holiday Cheer for Children’ Program With Families Around the World.

Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).

Advicenne (Euronext: ADVIC), announces is has received a positive opinion from the French Transparency Commission (HAS) with its lead asset, SibnayalTM eligible for reimbursement with a Moderate Level SMR (Medical Rendered Service) and a Level IV ASMR (Medical Rendered Service Improvement).

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the promotion of Joseph Vittiglio, JD, to Chief Business and Legal Officer.

Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced the addition of Joy Yan, M.D., Ph.D. to its Board of Directors.

Viridian Therapeutics, Inc. today announced the first subject was dosed in a Phase 1/2 proof-of-concept clinical trial for VRDN-001.

Biogen Inc. (Nasdaq: BIIB) today announced that, effective January 1, 2022, it will reduce the wholesale acquisition cost (WAC) of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for intravenous use in the United States by approximately 50%. For a patient of average weight (74 kg), the yearly cost at the maintenance dose (10 mg/kg) will be $28,200.